Related Experiment Video
Updated: Jul 25, 2025
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Quantitative profiling of genes associated with cancer pathways in brain tumors
Background:
Brain tumors are a heterogeneous group of malignancies characterized by inter- and intratumoral heterogeneity. Among them, the most aggressive and, despite advances in medicine, still incurable remains glioblastoma. One of the reasons is the high recurrence rate of the disease and resistance to temozolomide, a golden standard in chemotherapy of brain tumors. Therefore, mapping the pathways responsible for tumorigenesis at the transcriptional level may help to determine the causes and aggressive behavior among different glial tumors.
Patients And Methods:
Biopsies from patients with astrocytoma (N = 6), glioblastoma (N = 22), and meningioma (N = 14) were included in the sample set. A control group consisted of RNA isolated from healthy human brain (N = 3). The reverse-transcribed cDNAs were analyzed using the Human Cancer PathwayFinder™ real-time PCR Array in a 96-well format. The expression of 84 genes belonging to 9 signaling pathways (angiogenesis, apoptosis, cell cycle and senescence, DNA damage and repair, epithelial-to-mesenchymal transition, hypoxia, overall metabolism, and telomere dynamics) was determined for each sample.
Results:
By determining the relative expression of selected genes, we characterized the transcriptomic profile of individual brain malignancies in the context of signaling pathways involved in tumorigenesis. We observed deregulation in 50, 52.4 and 53.6% % of the genes in glioblastomas, meningiomas and astrocytomas, respectively. The most pronounced changes with statistical significance compared to control were observed in the genes associated with epithelial-to-mesenchymal transition (CDH2, FOXC2, GSC, SNAI2, and SOX10), cellular senescence (BMI1, ETS2, MAP2K1, and SOD1), DNA repair (DDB2, ERCC3, GADD45G, and LIG4), and dynamic of telomeres (TEP1, TERF2IP, TNKS, and TNKS2).
Conclusion:
Based on the obtained data, we can conclude that individual diagnoses differ in transcriptomic profile. An individual molecular approach is therefore necessary in order to provide comprehensive and targeted therapy on multiple metabolic pathways in the diagnosis of brain tumors.
Insights
This study reveals distinct transcriptomic profiles in brain tumors like glioblastoma, astrocytoma, and meningioma. Understanding these molecular differences is key for developing targeted therapies against aggressive brain cancers.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genomics
Background:
- Brain tumors exhibit significant heterogeneity, complicating treatment.
- Glioblastoma remains incurable due to high recurrence and temozolomide resistance.
- Transcriptional profiling is crucial for understanding glial tumor behavior.
Purpose of the Study:
- To characterize the transcriptomic profiles of astrocytoma, glioblastoma, and meningioma.
- To identify key signaling pathways involved in brain tumor development.
- To explore potential targets for novel therapeutic strategies.
Main Methods:
- Analysis of RNA from astrocytoma (N=6), glioblastoma (N=22), meningioma (N=14), and healthy brain (N=3) samples.
- Utilized the Human Cancer PathwayFinder™ real-time PCR Array to assess 84 genes across 9 key signaling pathways.
- Determined relative gene expression to map transcriptional profiles.
Main Results:
- Observed significant gene deregulation in all brain tumor types (50-53.6%).
- Highlighted significant alterations in genes related to epithelial-to-mesenchymal transition, cellular senescence, DNA repair, and telomere dynamics.
- Identified specific genes (e.g., CDH2, FOXC2, BMI1, DDB2, TEP1) with pronounced changes in glioblastomas, astrocytomas, and meningiomas compared to controls.
Conclusions:
- Distinct transcriptomic profiles exist for different brain tumor diagnoses.
- A personalized molecular approach is essential for effective brain tumor therapy.
- Targeting multiple metabolic pathways holds promise for comprehensive treatment strategies.
